Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Paired box protein Pax-6 (PAX6) mRNA is the messenger RNA transcript of the PAX6 gene, which encodes a master transcription factor critical for the development of the eyes, central nervous system, and pancreatic islets [1, 2]. PAX6 is essential for the specification of ocular tissues, and its precise dosage is vital for normal morphogenesis [3]. Mutations in the PAX6 mRNA, particularly nonsense mutations that result in premature termination codons, lead to a reduction in functional protein levels (haploinsufficiency), causing conditions such as aniridia and Peter's anomaly [4]. As a therapeutic target, PAX6 mRNA is addressed using nonsense suppression agents like ataluren, which facilitate the read-through of premature stop codons to restore the production of full-length, functional PAX6 protein [5]. Research into targeting PAX6 mRNA also explores antisense oligonucleotides and gene therapy to modulate expression levels in developmental and degenerative ocular diseases [6].
Nonsense mutation read-through (suppression of premature termination codons)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Paired box protein Pax-6 mRNA (PAX6 mRNA) (PAX6 mRNA).